Bacterin International Introduces OsteoSelect(R) DBM Putty
BELGRADE, Mont., March 10 /PRNewswire/ — Bacterin International, Inc. (Bacterin), a biologic company focused on the development of innovative, specialty allografts, announces the introduction of OsteoSelectÃ‚® DBM Putty for orthopedic bone grafting applications. OsteoSelectÃ‚® is a moldable allograft designed to withstand irrigation while exhibiting osteoinductive properties for improved bone regeneration. OsteoSelectÃ‚® will be an ideal complement to Bacterin’s current product portfolio, which focuses on optimizing handling characteristics and biologic performance of grafting materials for surgeons.
“The development and release of Bacterin’s first allograft based medical device represents another significant milestone in the evolution of Bacterin’s Biologics Division,” said Gregory Juda, PhD, Senior Biologics Scientist for Bacterin and product manager of OsteoSelectÃ‚® DBM Putty. Dr. Juda continued to say, “Bacterin used considerable input from the surgical community during the design of OsteoSelectÃ‚® DBM Putty and thus far, the feedback from orthopedic end users has been overwhelmingly positive. It was Bacterin’s goal to bring to the market a bone graft substitute that offers the surgeon excellent handling properties and device level sterility without compromising the biologic performance of the material. We have achieved that goal.”
OsteoSelectÃ‚® DBM Putty is a malleable bone grafting material comprised of demineralized bone matrix allograft suspended in a polymer carrier material. The product was engineered using feedback from key surgeons in several orthopedic specialties, with a focus on providing solutions to the shortcomings noted with other commercially available DBM products. The osteoinductive potential of every lot of terminally sterilized OsteoSelectÃ‚® is evaluated in an animal model prior to release thus providing surgeons with a bone grafting solution that is both safe and biologically active. Bacterin licensed the proprietary carrier technology from Osteotech Inc., and funding provided by a grant from the Montana Board of Research and Commercialization Technology was essential to the concept development and preclinical studies of the OsteoSelectÃ‚® product.
OsteoSelectÃ‚® DBM Putty will be commercially launched at the American Academy of Orthopaedic Surgeons in New Orleans, Louisiana, March 10-12.
Bacterin develops innovative products designed to enhance surgical capabilities and improve patient outcomes. Bacterin Biologics is a recognized leader in biomaterial design and musculoskeletal reconstruction. Bacterin’s proprietary biologic scaffolds include OsteoSpongeÃ‚®, OsteoWrapÃ‚®, OsteoLockÃ‚®, and BacFastÃ‚®. Bacterin’s Devices Division is committed to the development of bioactive coating technologies for medical devices.
Certain matters discussed in this press release are forward-looking statements with regards to the Company’s future plans, objectives, and anticipated performance. These forward-looking statements can generally be identified as such because the context of the statement will include words, such as Bacterin International, Inc. “expects,” “should,” “believes,” “anticipates” or words of similar import. Bacterin International, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions; the Company cannot give any assurance that the expectations will be attained. These forward-looking statements are only made as of the date of this press release; Bacterin International, Inc. undertakes no obligation to publicly update this information.
For more information regarding Bacterin, or this press release, please visit www.bacterin.com.
SOURCE Bacterin International, Inc.